Results 1 to 10 of about 4,474 (115)

Dihydroartemisinin-piperaquine plus sulfadoxine-pyrimethamine versus either drug alone for intermittent preventive treatment of malaria in pregnancy: A double-blind, randomized, controlled phase 3 trial from Uganda. [PDF]

PLoS Medicine
BackgroundTo mitigate adverse consequences of malaria in pregnancy, the World Health Organization recommends intermittent preventive treatment of malaria in pregnancy (IPTp) with sulfadoxine-pyrimethamine.
Abel Kakuru, Jimmy Kizza, Miriam Aguti, Harriet Adrama, John Ategeka, Peter Olwoch, Miriam Nakalembe, Joaniter I Nankabirwa, Bishop Opira, Nida Ozarslan, Anju Ranjit, Erin Dela Cruz, Tamara D Clark, Michelle E Roh, Stephanie L Gaw, Prasanna Jagannathan, Philip J Rosenthal, Moses R Kamya, Grant Dorsey   +18 more
doaj   +2 more sources

Physiologically‐Based Pharmacokinetic Modeling to Investigate Piperaquine Exposure in Pregnant Women Using an Individualized Profile Approach [PDF]

Clinical and Translational Science
Malaria in pregnancy poses significant risks to the mother, fetus, and neonate, necessitating effective treatment and prevention strategies. This study explored the application of an individualized (‘virtual twin’) physiologically‐based pharmacokinetic ...
Sonia Khier, Myriam El Gaaloul, Joel Tarning, Nada Abla   +3 more
doaj   +2 more sources

Dihydroartemisinin-piperaquine versus sulfadoxine-pyrimethamine for intermittent preventive treatment of malaria in pregnancy: a systematic review and individual participant data meta-analysisResearch in context [PDF]

EClinicalMedicine
Summary: Background: High-grade Plasmodium falciparum resistance to sulfadoxine-pyrimethamine in east and southern Africa has prompted trials evaluating intermittent preventive treatment in pregnancy (IPTp) with dihydroartemisinin-piperaquine as an ...
Michelle E. Roh, Julie R. Gutman, Maxwell Murphy, Jenny Hill, Mywayiwawo Madanitsa, Abel Kakuru, Hellen C. Barsosio, Simon Kariuki, John P.A. Lusingu, Frank Mosha, Richard Kajubi, Moses R. Kamya, Don Mathanga, Jobiba Chinkhumba, Miriam K. Laufer, Eulambius Mlugu, Appolinary A.R. Kamuhabwa, Eleni Aklillu, Omary Minzi, Roland Nnaemeka Okoro, Ado Danazumi Geidam, John David Ohieku, Meghna Desai, Prasanna Jagannathan, Grant Dorsey, Feiko O. ter Kuile   +25 more
doaj   +2 more sources

Development and Validation of a Novel Diagnostic Model for Childhood Autism Spectrum Disorder Based on Ferroptosis-Related Genes

Frontiers in Psychiatry, 2022
Autism spectrum disorder (ASD) is a highly genetic heterogeneous neurodevelopmental disorder, which is usually considered a heritable and heterogeneous neurodevelopmental disorder and has caused a great burden to society and families.
Xiaolu Wu, Ran Li, Qin Hong, Xia Chi
doaj   +1 more source

Systematic Review and Pharmacological Considerations for Chloroquine and Its Analogs in the Treatment for COVID-19

Frontiers in Pharmacology, 2020
COVID-19 has been announced pandemic by WHO and over 17,000,000 people infected (Till April 21st 2020). The disease is currently under control in China, with a curative rate of 86.8%.
Hongwei Peng, Zhangren Chen, Yunyun Wang, Simei Ren, Simei Ren, Simei Ren, Tiantian Xu, Xin Lai, Jinhua Wen, Mengjun Zhao, Chuanfei Zeng, Lijuan Du, Yanmei Zhang, Li Cao, Jinfang Hu, Xiaohua Wei, Tao Hong   +16 more
doaj   +1 more source

Combining antimalarial drugs and vaccine for malaria elimination campaigns: a randomized safety and immunogenicity trial of RTS,S/AS01 administered with dihydroartemisinin, piperaquine, and primaquine in healthy Thai adult volunteers

Human Vaccines & Immunotherapeutics, 2020
Introduction: RTS,S/AS01 is currently the most advanced malaria vaccine but provides incomplete, short-term protection. It was developed for use within the expanded program on immunizations (EPI) for African children. Another use could be adding mass RTS,
Lorenz von Seidlein, Borimas Hanboonkunupakarn, Podjanee Jittamala, Pongphaya Pongsuwan, Kesinee Chotivanich, Joel Tarning, Richard M. Hoglund, Markus Winterberg, Mavuto Mukaka, Pimnara Peerawaranun, Pasathorn Sirithiranont, Zoe Doran, Christian F. Ockenhouse, Karen Ivinson, Cynthia Lee, Ashley J. Birkett, David C. Kaslow, Pratap Singhasivanon, Nicholas P.J. Day, Arjen M. Dondorp, Nicholas J. White, Sasithon Pukrittayakamee   +21 more
doaj   +1 more source

Late dihydroartemisinin-piperaquine treatment failure of P. falciparum malaria attack related to insufficient dosing in an obese patient

IDCases, 2023
We report the case of an obese patient who experienced late failure on day28 of a well-conducted treatment with artesunate, followed by dihydroartemisinin-piperaquine (DHA-PPQ) for a severe P. falciparum malaria attack. The same P.
M. Parisey, S. Houze, J. Bailly, N. Taudon, K. Jaffal, N. Argy, C. Rouzaud, B. Mégarbane, S. Lariven, Y. Yazdanpanah, S. Matheron   +10 more
doaj   +1 more source

Efficacy comparison between anti-malarial drugs in Africans presenting with mild malaria in the Central Republic of Africa: a preliminary study

Parasite, 2005
Drug resistance to Plasmodium falciparum contributes to major health problems in central Africa and, as a consequence, poverty. We have analyzed the efficacy of three currently available antimalarial drugs to treat symptomatic, uncomplicated P ...
Nambei W.S., Gbagba F.E., Ndémanga J., Doui-Doumgba K., Diallo T.O., Ndadjimbaye V., Flori P., Perraut R., Garraud O.   +8 more
doaj   +1 more source

Plasmodium falciparum Plasmepsin 2 Duplications, West Africa

Emerging Infectious Diseases, 2018
Dihydroartemisinin/piperaquine (DHA/PPQ) is increasingly deployed as an antimalaria drug in Africa. We report the detection in Mali of Plasmodium falciparum infections carrying plasmepsin 2 duplications (associated with piperaquine resistance) in 7/65 ...
Juliana Inoue, Miguel Silva, Bakary Fofana, Kassim Sanogo, Andreas Mårtensson, Issaka Sagara, Anders Björkman, Maria Isabel Veiga, Pedro Eduardo Ferreira, Abdoulaye Djimde, José Pedro Gil   +10 more
doaj   +1 more source

Prevalence of mutations in the Plasmodium falciparum chloroquine resistance transporter, PfCRT, and association with ex vivo susceptibility to common anti-malarial drugs against African Plasmodium falciparum isolates

Malaria Journal, 2020
Background The Plasmodium falciparum chloroquine transporter gene (pfcrt) is known to be involved in chloroquine and amodiaquine resistance, and more particularly the mutations on the loci 72 to 76 localized within the second exon.
Francis Tsombeng Foguim, Hervé Bogreau, Mathieu Gendrot, Joel Mosnier, Isabelle Fonta, Nicolas Benoit, Rémy Amalvict, Marylin Madamet, Sharon Wein, Bruno Pradines, The French National Reference Centre for Imported Malaria Study Group   +10 more
doaj   +1 more source